Boston Scientific  (BSX - Get Report) shares were up nearly 2% Friday afternoon after the company announced the $435 million purchase of Swiss heart valve device maker Symetis

Symetis is a structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices.